Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil as First-Line Therapy in Advanced or Recurrent Endometrial Carcinoma
NCT00005861Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- May 2000
- Primary completion
- Aug 2005
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in endometrial cancer (EC), sponsored by GOG Foundation. Primary endpoints: Objective Response Rate and Safety and Tolerability. Started May 2000; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT00005861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005861.